Psychiatry
Show:
Professional Education
Alzheimer's 8: Dementia Update for PCPs: Disease-Modifying Medications Risks and Benefits
A panel of dementia specialists provide up-to-date information on new disease-modifying medications receiving FDA approval, but with specific candidate criteria. Practitioners will learn how these medications work, which of their patients may benefit, how to identify and address risks, and how to effectively communicate with patients and family members. [1.50 AMA PRA Category 1 Credits™, 1.50 Contact Hours (ANCC)]
Dec 21, 2023
Suicide Prevention: Primary Care Is a Crucial Setting for Identifying Risk
At any given time, some of your patients are having thoughts of suicide. Effective suicide prevention requires a comprehensive approach.
Nov 07, 2023
Reducing Risk in Psychiatry Through Effective Medication Management
Medication regimens for psychiatric patients can be highly complex and involve a variety of drugs. Incorporating the medication management strategies outlined here can help psychiatrists keep patients safe.
Oct 30, 2023
Off-Label Use: Patient Safety Implications
The standard for appropriate off-label use of medications and other products is what other similarly trained physicians would do, not what the manufacturer of the medication or product recommends.
Oct 01, 2023
Suicide and Crisis Lifeline: Call or Text 988
The National Suicide Prevention Lifeline is now 988, an easy-to-remember number for 24/7 crisis care.
Sep 22, 2022
Mental Health Providers: Balancing Privacy With Public Welfare
Since spring 2020, patients have reported ideation of harm with increasing frequency. These encounters create a moral dilemma for mental health providers, who must maintain provider-patient privilege while adhering to legal reporting obligations for protecting the public welfare.
Professional Education
Alzheimer's 7: Questions and Answers - What Physicians Ask About Diagnosing and Treating Dementia
This course focuses on the common concerns and questions expressed by clinicians about dementia and cognitive impairment. Practitioners will learn more about making the initial observation of cognitive decline and beginning a conversation with older adult patients, overcoming common barriers to making a definitive diagnosis of dementia, and managing the ongoing clinical needs of patients experiencing dementia. Experienced clinicians engage in conversation on how they handle delicate and difficult conversations with patients and their family members. Program participants will become knowledgeable of warning signs of dementia, gain proficiency in screening and evaluating adults for cognitive deficits, confidently disclose a diagnosis of dementia, and communicate next steps to patients and family caregivers, including safety issues, medications, and community resources. [1.50 AMA PRA Category 1 Credits™, 1.50 Contact Hours (ANCC)]
Professional Education
Alzheimer's 6: Pharmacological Management of Behavioral and Psychological Symptoms of Dementia
Join our self-paced educational program to learn to distinguish dementia symptoms from other psychiatric issues and treat them with pharmacological interventions. Improve recognition of behavioral problems in Alzheimer's and dementia patients, use the DICE psycho-behavioral model for medication decisions, and create treatment plans with behavioral and pharmacological strategies to refine your best practices for individuals with dementia. [1.50 AMA PRA Category 1 Credits™, 1.50 Contact Hours (ANCC)]
Professional Education
Alzheimer's 5 : Use of Pharmacotherapy for Patients with Major Neurocognitive Disorder
This activity includes video lectures and is the fifth in a series of courses that seek to educate clinicians on standardized screening, evaluation, and disease management of Alzheimer's disease and related dementias. This fifth course focuses on the most frequently used and FDA-approved prescription medications for Alzheimer's disease and dementias, the current research regarding its use, and guidelines for prescribing and discontinuing medication. The program will incorporate cultural values and beliefs when creating and sharing the pharmacological care plan. [1.75 AMA PRA Category 1 Credits™, 1.75 Contact Hours (ANCC)]
Professional Education
Alzheimer's 4: Addressing Patients' and Families' Needs through the Disease Stages of Dementia
This is the fourth session in an eight-part educational series that focuses on standardized screening, evaluation, and disease management of Alzheimer’s disease and related dementias. This course covers life planning throughout disease stages, assessing and assisting caregivers, enhancing communications, utilizing community resources, and end-of-life decision-making. It addresses sensitive conversations with patients, families, and caregivers. [2.00 AMA PRA Category 1 Credits™, 2.00 Contact Hours (ANCC)]
Professional Education
Alzheimer's 3: Addressing and Managing Behavioral and Environmental Symptoms of Dementia
This activity is the third in a series of eight courses that seek to educate clinicians on standardized screening, evaluation, and disease management of Alzheimer’s disease and related dementias. This third course focuses on using the DICE method to assess behavioral symptoms of dementia and create and evaluate treatment plans. This course also covers the careful use of medication during disease management and common behavioral issues with dementia patients including tools for management of these behaviors. [1.50 AMA PRA Category 1 Credits™, 1.75 Contact Hours (ANCC)]
Professional Education
Alzheimer's 1: Screening for Dementia Among Adults with Cognitive Decline
This activity is the first in a series of eight courses that seek to educate clinicians on standardized screening, evaluation, and disease management of Alzheimer’s disease and related dementias. This first course focuses on introducing the Alzheimer’s Project and highlighting the increasingly important role of practitioners in dementia care. The course also introduces the Alzheimer’s Project cognitive impairment screening algorithm and screening instruments and covers addressing reversible conditions that may present similar symptoms to cognitive impairment. [1.25 AMA PRA Category 1 Credits™, 1.25 Contact Hours (ANCC)]